ESR1 and Hyperglycemia: In the combinations of antiestrogens + alpelisib, high grade adverse events, including hyperglycemia, rash, and diarrhea are common and mutations in PTEN and ESR1 were associated with disease progression and resistance to the combinations [54, 55].